Aurinia Pharmaceuticals (AUPH)

• Market cap: $1.32B
• 1 day: 2.45%
• 5 days: 0.55%
• 1 month: 5.63%
• 3 months: 28.49%
• 6 months: 66.97%
• Year to date: 5.26%
• 1 year: -1.29%
• 5 years: -57.05%
• 10 years: 152.05%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Employees: 300

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 20

31% more capital invested

Capital invested by funds: $321M [Q2] → $420M (+$99M) [Q3]

11% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 45

6% more funds holding

Funds holding: 168 [Q2] → 178 (+10) [Q3]

0.78% more ownership

Funds ownership: 39.37% [Q2] → 40.15% (+0.78%) [Q3]

58% less call options, than puts

Call options by funds: $13.4M | Put options by funds: $31.7M